• Explore /
  • Poster
  • / A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led study.

A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led study.

Abstract Poster

Authors

null

Deirdre Cohen

New York University Cancer Institute

Deirdre Cohen , Paul Christos , Joseph Sparano , Hedy Kindler , Daniel Catenacci , Tanios Bekaii-Saab , Sanaa Tahiri , Yelena Janjigian , Michael Gibson , Emily Chan , Lakshmi Rajdev , Susan Urba , James Wade , Peter Kozuch , Erica Love , Katherine Vandris , Naoko Takebe , Howard Hochster

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session A: Cancers of the Esophagus and Stomach

Track

Cancers of the Esophagus and Stomach

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT00982592

Citation

J Clin Oncol 31, 2013 (suppl 4; abstr67)

DOI

10.1200/jco.2013.31.4_suppl.67

Abstract #

67

Poster Bd #

B11

Abstract Disclosures

Similar Posters

First Author: Deirdre Jill Cohen

First Author: D. J. Cohen

Poster

2020 ASCO Virtual Scientific Program

Final results of a phase II trial of first-line FOLFIRINOX for advanced gastroesophageal cancers.

Final results of a phase II trial of first-line FOLFIRINOX for advanced gastroesophageal cancers.

First Author: Ramon Jin

First Author: Ana De Jesus-Acosta